MAIA Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement.

MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting.

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $2.44 Million Private Placement.

MAIA Biotechnology Announces $2.44 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics.

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer.

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference.

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

On Tuesday, MAIA Biotechnology Inc MAIA announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc's REGN cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens.

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent.

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy.

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent.

MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer.

MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at the BIO International Convention 2024.

MAIA Biotechnology to Present at the BIO International Convention 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement.

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement.

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.00 Million Private Placement.

MAIA Biotechnology Announces $1.00 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero.

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.33 Million Private Placement.

MAIA Biotechnology Announces $1.33 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement.

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board.

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Participate in the 36th Annual ROTH Conference.

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at AACR Annual Meeting.

MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients.

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders.

News for MAIA Biotechnology Inc Stock (MAIA)